Last reviewed · How we verify

Levobupivacaine and Fentanyl

Hamad Medical Corporation · FDA-approved active Small molecule

Levobupivacaine blocks sodium channels to provide local anesthesia, while fentanyl activates opioid receptors to provide analgesia.

Levobupivacaine blocks sodium channels to provide local anesthesia, while fentanyl activates opioid receptors to provide analgesia. Used for Local and regional anesthesia with analgesia.

At a glance

Generic nameLevobupivacaine and Fentanyl
SponsorHamad Medical Corporation
Drug classLocal anesthetic with opioid analgesic combination
TargetVoltage-gated sodium channels; mu-opioid receptor
ModalitySmall molecule
Therapeutic areaAnesthesia and Pain Management
PhaseFDA-approved

Mechanism of action

Levobupivacaine is the S-enantiomer of bupivacaine that reversibly inhibits sodium influx in nerve fibers, preventing action potential propagation and local anesthetic effect. Fentanyl is a synthetic opioid agonist that binds to mu-opioid receptors in the central and peripheral nervous system to produce analgesia and potentiate the analgesic effect of the local anesthetic.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: